FDA Approves BRIVARACETAM — Micro Labs Limited

# FDA Approves Generic Brivaracetam Intravenous Formulation Micro Labs Limited has received FDA approval for a generic intravenous brivaracetam formulation (ANDA214880), marking a significant market entry into the anticonvulsant segment and enabling more competitive pricing for this adjunctive epilepsy therapy. The approval of the injectable generic is expected to reduce treatment costs for hospital and clinical settings, intensifying competition in the brivaracetam market as the originator product faces increased generic pressure.